EXCLUSIVE: Hoth Therapeutics To Rebrand To Pursue AI Chip Technologies

Hoth Therapeutics Inc. (NASDAQ:HOTH) on Tuesday said it plans to rebrand as Rocket One Inc. and restructure its operations to focus on artificial intelligence infrastructure, semiconductor technologies, and ultra-low-power AI computing through a newly formed wholly owned subsidiary.

The company said the strategic shift was unanimously approved by its board and is aimed at positioning the business within the growing AI semiconductor market.

Hoth added that it secured exclusive rights to AI semiconductor acceleration and spintronic computing technologies developed at Virginia Commonwealth University.

Read Also: Hoth Therapeutics Early Cancer Trial Succeeds With 100% Patient Response, Cuts Disease Severity By Half

Company Targets AI Power And Efficiency Challenges

Under the proposed Rocket One brand, the company intends to focus on technologies designed to address mounting infrastructure pressures tied to artificial intelligence workloads, including power consumption, cooling limitations, memory bottlenecks, and inference latency.

Rocket One Secures Exclusive Semiconductor Technology Rights

The company said one of the licensed technologies involves a nanomagnetic matrix multiplier intended to function as a hardware accelerator for machine learning and AI applications.

According to Hoth, the architecture is designed to support ultra-low-power AI acceleration, advanced memory efficiency, distributed AI infrastructure, and intelligent autonomous platforms.

The second licensed technology centers on spintronic memory systems that use electron spin rather than conventional charge-based semiconductor methods.

The company said the technology could have applications across defense infrastructure, aerospace systems, radiation-tolerant computing, and orbital AI environments.

Company To Maintain Biotechnology Operations

Hoth said it plans to continue its biotechnology programs and is evaluating the creation of a separate wholly owned subsidiary for its therapeutic development pipeline.

HOTH Price Action: Hoth Therapeutics shares were down 9.69% at $0.55 during premarket trading on Tuesday, according to Benzinga Pro.

Over the past month, HOTH has declined about 20.9% versus a 4.2% rise in the S&P 500 and is down roughly 46% year-to-date compared to the index’s 7.7% gain.

Image Via Shutterstock

Read Also: Michael Burry Says Today's AI Debt Bubble Mirrors The Dot-Com Era

UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets.

This article EXCLUSIVE: Hoth Therapeutics To Rebrand To Pursue AI Chip Technologies originally appeared on Benzinga.com

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.